Abstracts tagged "ANCA"

Abstract Number: 1750 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Factor Titer Is Inversely Correlated with ANCA Titer and Relates to Characteristic Manifestations in Patients with Eosinophilic Granulomatosis with Polyangiitis
Jun Inamo, Yuko Kaneko, Yuichiro Ota and Tsutomu Takeuchi, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), which is characterized by vasculitis with allergic features such as…
Abstract Number: 2718 • 2018 ACR/ARHP Annual Meeting
Comparison of Various ANCA Detection Methods in Predominantly MPO ANCA-Associated Vasculitis Cohort
Yasuhiro Katsumata¹, Ken-ei Sada², Tomohiro Kameda³, Hiroaki Dobashi³, Hisashi Yamanaka⁴ and Masayoshi Harigai⁵, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama, Japan, ³Internal Medicine Division of Hematology, Rheumatology, and Respiratory Medicine, Kagawa University, Kagawa, Japan, ⁴Institute of Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁵Tokyo Women's Medical University, Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo, Japan
Background/Purpose: In 2017, the multicenter European Vasculitis Study Group (EUVAS) evaluated the diagnostic accuracy of a wide spectrum of detection tests of MPO and PR3-ANCAs…
Abstract Number: 2743 • 2018 ACR/ARHP Annual Meeting
Favorable Efficacy of Rituximab in ANCA-Associated Vasculitis Patients with Excessive B Cell Differentiation
Yusuke Miyazaki¹, Shingo Nakayamada¹, Satoshi Kubo¹, Kazuhisa Nakano¹, Shigeru Iwata², Shunsuke Fukuyo³, Akio Kawabe⁴ and Yoshiya Tanaka⁵, ¹First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³University of Occupational and Environmental Health, Japan, Fukuoka, Japan, ⁴University of Occupational and Environmental Health, Japan, Kitakyusyu, Japan, ⁵University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: B cell depletion by rituximab (RTX)is effective treatment for ANCA-associated vasculitis (AAV). However, the phenotype of peripheral B cells and the selection criteria for…
Abstract Number: 1751 • 2018 ACR/ARHP Annual Meeting
Interstitial Lung Disease during ANCA-Associated Vasculitis: A Poor-Prognosis Factor
Thibault Maillet¹, Tiphaine Goletto², Guillaume Beltramo³, Henry Dupuy⁴, Stéphane Jouneau⁵, Raphaël Borie⁶, Bruno Crestani⁶, Vincent Cottin⁷, Daniel Blockmans⁸, Estibaliz Lazaro⁴, Jean-Marc Naccache⁹, Grégory Pugnet¹⁰, Hilario Nunes¹¹, Mathilde De Menthon¹², Hervé Devilliers¹³, Philippe Bonniaud³, Xavier Puéchal¹⁴, Luc Mouthon¹⁴, Bernard Bonnotte¹, Loïc Guillevin¹⁵, Benjamin Terrier¹⁴ and Maxime Samson¹, ¹Service de Médecine Interne et Immunologie Clinique, CHU de Dijon, Dijon, France, ²Service de Pneumologie, Hôpital Saint-Louis, APHP, Paris, France, ³Service de Pneumologie, CHU de Dijon, Dijon, France, ⁴Service de Médecine Interne et Maladies Infectieuses, Hôpital Haut-Lévêque, Bordeaux, France, ⁵Service de Pneumologie, CHU de Rennes; IRSET UMR 1085, Université de Rennes 1, Rennes, France, ⁶Service de Pneumologie, Hôpital Bichat, APHP, Paris, France, ⁷Service de Pneumologie, Hôpital Louis-Pradel, Bron, France, ⁸Rheumatology, UZ Leuven, Leuven, Belgium, ⁹Service de Pneumologie, Hôpital Tenon, APHP, Paris, France, ¹⁰Service de Médecine Interne, CHU de Toulouse, Toulouse, France, ¹¹Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, ¹²Service de Médecine Interne, Hôpital Bicêtre, APHP, Le Kremlin-Bicêtre, France, ¹³Service de Médecine Interne et Maladies Systémiques, CHU de Dijon, Dijon, France, ¹⁴Centre de Référence des Maladies Auto-immunes et Systémiques Rares, Vascularites Nécrosantes et Sclérodermie Systémique, Service de Médecine Interne, Hôpital Cochin, APHP, INSERM U1016, Université Paris Descartes, Paris, France, ¹⁵Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France
Background/Purpose: Interstitial lung disease (ILD), rarely described in ANCA-associated vasculitis (AAV) patients, was mainly associated with anti-MPO ANCA. ILD’s prognostic value remains unclear. This study…
Abstract Number: 2719 • 2018 ACR/ARHP Annual Meeting
Tracking the Risk of Infections in ANCA-Associated Vasculitis: Results from a Scottish Matched-Cohort Study
Shifa Sarica¹, Neeraj Dhaun², Jan Sznajd³, John Harvie³, Nicola Joss³, John McLaren⁴, Lucy McGeoch⁵, Nicole Amft⁶, Vinod Kumar⁷, Angharad Marks¹, Corri Black¹ and Neil Basu¹, ¹Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom, ²University/British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom, ³Department of Rheumatology, Raigmore Hospital, Inverness, United Kingdom, ⁴Fife Rheumatic Diseases Unit, Whyteman's Brae Hospital, Kirkcaldy, United Kingdom, ⁵Center for Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow, United Kingdom, ⁶Department of Rheumatology, Western General Hospital, Edinburgh, United Kingdom, ⁷Rheumatology Department, Ninewells Hospital, Dundee, United Kingdom
Background/Purpose: Evaluation of infection risk in ANCA-associated vasculitis (AAV) has been limited to small, selected populations and/or serious episodes. In this large study, we aimed…
Abstract Number: 2788 • 2018 ACR/ARHP Annual Meeting
The Effects of Plasma Exchange and Reduced-Dose Glucocorticoids during Remission-Induction for Treatment of Severe ANCA-Associated Vasculitis
Michael Walsh¹, Peter A. Merkel² and David Jayne³, ¹Nephrology, McMaster University, Hamilton, ON, Canada, ²Division of Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Department of Medicine, University of Cambridge, Cambridge, United Kingdom
Background/Purpose: It is uncertain whether plasma exchange improves clinical outcomes in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Also uncertain is whether, compared to standard therapy with…
Abstract Number: 1752 • 2018 ACR/ARHP Annual Meeting
Asthma in Eosinophilic Granulomatosis with Polyangiitis Treated with Rituximab
Marta Casal Moura¹, Alvise Berti², Karina Keogh², Gerald Volcheck³, Ulrich Specks⁴ and Misbah Baqir⁵, ¹Pulmonary and Critical Care, Thoracic Disease Research Unit, Mayo Clinic College of Medicine, Rochester, MN, ²Pulmonary and Critical Care, Mayo Clinic College of Medicine, Rochester, MN, ³Allergic Diseases, Internal Medicine Department, Mayo Clinic College of Medicine, Rochester, MN, ⁴Mayo Clinic College of Medicine, Rochester, MN, ⁵Pulmonary/Critical Care, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare systemic small-vessel necrotizing vasculitis presenting with asthma and eosinophilia. Anti-neutrophil cytoplasmic antibodies (ANCA) association may influence…
Abstract Number: 2721 • 2018 ACR/ARHP Annual Meeting
Venous Thromboembolism in ANCA Associated Vasculitis. a Population-Based Cohort Study from Southern Sweden
Matina Liapi¹, David Jayne², Mårten Segelmark³ and Aladdin Mohammad⁴, ¹Medicine, Blekinge Hospital, Karlskrona, Sweden, ²Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ³Clinical Sciences, Nephrology, Lund University, Lund, Sweden, ⁴Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden
Background/Purpose: To estimate the rate and predictors of venous thromboembolic events (VTEs) in a population-based cohort of patients with ANCA- associated vasculitis (AAV). Methods: 322…
Abstract Number: 2852 • 2018 ACR/ARHP Annual Meeting
Excessive Formation of Neutrophil Extracellular Traps: Different Role in the Pathogenesis of ANCA-Associated Vasculitis and Systemic Lupus Erythematosus
Laura van Dam¹, Tineke Kraaij¹, Sylvia W.A. Kamerling¹, Hans U. Scherer², Ton Rabelink¹, Cees van Kooten¹ and Y.K. Onno Teng¹, ¹Nephrology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: ANCA-associated vasculitis (AAV) and systemic lupus erythematosus (SLE) both cause glomerulonephritis with pauci-immune and full-house immunofluorescence patterns, respectively. Although AAV and SLE are clinically…
Abstract Number: 1753 • 2018 ACR/ARHP Annual Meeting
Interstitial Lung Disease in ANCA-Associated Vasculitis Defines a Unique Subgroup of Patients at High Risk for Respiratory Death: A Cluster Analysis
Zachary Wallace¹, Yuqing Zhang², John H. Stone³ and Hyon K. Choi⁴, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ³Home Address, Sudbury, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA
Background/Purpose: ANCA-associated vasculitis (AAV) has a propensity for heterogeneous organ involvement. ANCA specificity has increasingly been favored over clinical diagnosis (e.g., microscopic polyangiitis) for subgrouping…
Abstract Number: 2722 • 2018 ACR/ARHP Annual Meeting
Incidence and Predictors of Severe Infections in ANCA Associated Vasculitis in a Population-Based Cohort – Preliminary Results
Jens Rathmann¹, David Jayne², Goran Jönsson³, Mårten Segelmark⁴, Jan-Åke Nilsson⁵ and Aladdin Mohammad², ¹Rheumatology, Skanes University Hospital, Lund, Lund, Sweden, ²Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ³Clinical Sciences Lund, Department of Infection Medicine, Lund University, Lund, Sweden, ⁴Clinical Sciences, Nephrology, Lund University, Lund, Sweden, ⁵Department of Rheumatology, Skåne University Hospital, Malmö, Sweden
Background/Purpose: To determine the incidence rates, predictors and outcome of severe infections in ANCA associated vasculitis (AAV). Methods: We conducted a population-based cohort study in…
Abstract Number: 2971 • 2018 ACR/ARHP Annual Meeting
Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease: Long Term Outcomes
Joanna Tieu^1,2, Seerapani Gopaluni^3,4, Rona Smith¹ and David Jayne¹, ¹Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ²Department of Medicine, University of Adelaide, Adelaide, Australia, ³Medicine, University of Cambridge, Cambridge, United Kingdom, ⁴Vasculitis and Lupus, Addenbrooke’s Hospital, Cambridge, United Kingdom
Background/Purpose: Despite a low incidence of hypogammaglobulinemia (HG) in clinical trials using rituximab (RTX), HG occurs in follow-up of patients with autoimmune disease. Immunoglobulin replacement…
Abstract Number: 1758 • 2018 ACR/ARHP Annual Meeting
A 24 Month Analysis of Rituximab Safety and Efficacy in Eosinophilic Granulomatosis with Polyangiitis
Vítor Teixeira^1,2, Aladdin Mohammad^1,3 and David Jayne¹, ¹Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ²Rheumatology Department, CHLN - Santa Maria Hospital, Lisbon Academic Medical Center, Lisbon, Portugal, ³Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) frequently pursues a refractory course leading to high glucocorticoid exposure and toxicity. A previous retrospective study found rituximab (RTX)…
Abstract Number: 2725 • 2018 ACR/ARHP Annual Meeting
Clinical Characteristics and Long-Term Follow-up of 382 Microscopic Polyangiitis Patients
Yann Nguyen¹, Christian Pagnoux², Alexandre Karras³, Thomas Quémeneur⁴, Francois Maurier⁵, Mohamed Hamidou⁶, Alain Le Quellec⁷, Noémie Jourde-Chiche⁸, Pascal Cohen¹, Alexis Régent¹, François Lifermann⁹, Arsène Mékinian¹⁰, Chahéra Khouatra¹¹, Eric Hachulla¹², Jacques Ninet¹³, Jacques Pourrat¹⁴, Marc Ruivard¹⁵, Pascal Godmer¹⁶, Jean-Francois Viallard¹⁷, Benjamin Terrier¹, Luc Mouthon¹, Loïc Guillevin¹ and Xavier Puéchal¹, ¹Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ²Division of Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ³Department of Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, Paris, France, ⁴Department of Internal Medicine, CH of Valenciennes, France, Valenciennes, France, ⁵Médecine interne, Hôpitaux Privés de Metz, Metz, France, ⁶Department of Internal Medicine, CHU de Nantes, France, Nantes, France, ⁷Department of Internal Medicine, Hôpital Saint-Eloi, CHU de Montpellier, France, Montpellier, France, ⁸Nephrology, Department of Nephrology, AP-HM, CHU Conception, Marseille, France, Marseille, France, ⁹Dax, Dax, France, ¹⁰Department of Internal Medicine, Hôpital Saint-Antoine, APHP, Paris, France, Paris, France, ¹¹Department of Respiratory Medicine, National Reference Center for Rare Pulmonary Diseases, Hospices civils de Lyon, Hôpital Louis Pradel, Lyon, France, Lyon, France, ¹²Department of Internal Medicine, National Reference Center for Systemic Sclerosis, Hôpital Claude Huriez, CHRU Lille, France, Lille, France, ¹³Department of Internal Medicine, Hôpital Edouard Herriot HCL, CHU de Lyon, France, Lyon, France, ¹⁴Department of Nephrology, Hôpital de Rangueil, CHU Toulouse, France, Toulouse, France, ¹⁵Department of Internal Medicine, CHU Estang, Clermont-Ferrand, France, Clermont-ferrand, France, ¹⁶Department of Internal Medicine, CH Vannes, France, Vannes, France, ¹⁷Department of Internal Medicine, Hôpital Haut-Lévêque, Bordeaux, France, CHU Bordeaux, France
Background/Purpose: Microscopic polyangiitis (MPA) is a systemic ANCA-associated small-vessel necrotizing vasculitis characterized by general symptoms, and visceral manifestations, including rapidly progressive glomerulonephritis and alveolar hemorrhage.…
Abstract Number: 1761 • 2018 ACR/ARHP Annual Meeting
Evaluation of the Functional Activity of Endothelial Progenitor Cells in Patients with ANCA-Associated Vasculitis
Ana Paula Toledo Del Rio¹, Stephanie Ospina Prieto¹, Bruno Kosa Lino Duarte¹, Manoel Barros Bertolo^1,2, Margareth de Castro Ozelo¹ and Zoraida Sachetto¹, ¹Internal Medicine, Faculty of Medical Science - State University of Campinas/Unicamp, Campinas, Brazil, ²INTERNAL MEDICINE, DISCIPLINE OF RHEUMATOLOGY, Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, Brazil
Background/Purpose: ANCA-associated vasculitis (AAV) are relapsing diseases with high morbidity and mortality. The vascular damage present in these patients requires continuous repair with the participation…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].